Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their Destruction During the Development of Type 1 Diabetes.

Anquetil F, Mondanelli G, Gonzalez N, Rodriguez Calvo T, Zapardiel Gonzalo J, Krogvold L, Dahl-Jørgensen K, Van den Eynde B, Orabona C, Grohmann U, von Herrath MG.

Diabetes. 2018 Sep;67(9):1858-1866. doi: 10.2337/db17-1281. Epub 2018 Jun 26.

2.

Distinct Housing Conditions Reveal a Major Impact of Adaptive Immunity on the Course of Obesity-Induced Type 2 Diabetes.

Sbierski-Kind J, Kath J, Brachs S, Streitz M, von Herrath MG, Kühl AA, Schmidt-Bleek K, Mai K, Spranger J, Volk HD.

Front Immunol. 2018 May 28;9:1069. doi: 10.3389/fimmu.2018.01069. eCollection 2018.

3.

Oral insulin does not alter gut microbiota composition of NOD mice.

Kihl P, Krych L, Buschard K, Wesley JD, Kot W, Hansen AK, Nielsen DS, von Herrath MG.

Diabetes Metab Res Rev. 2018 Sep;34(6):e3010. doi: 10.1002/dmrr.3010. Epub 2018 May 1.

PMID:
29637693
4.

Suppression of diabetes by accumulation of non-islet-specific CD8+ effector T cells in pancreatic islets.

Christoffersson G, Chodaczek G, Ratliff SS, Coppieters K, von Herrath MG.

Sci Immunol. 2018 Mar 23;3(21). pii: eaam6533. doi: 10.1126/sciimmunol.aam6533.

PMID:
29572238
5.

OAS1 is not associated with MHC class I hyperexpression in the islets of donors with T1D regardless of disease duration.

Sabouri S, Mikulski Z, von Herrath MG.

Clin Immunol. 2018 Jun;191:34-36. doi: 10.1016/j.clim.2018.03.006. Epub 2018 Mar 15. No abstract available.

PMID:
29551703
6.

α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes.

Brissova M, Haliyur R, Saunders D, Shrestha S, Dai C, Blodgett DM, Bottino R, Campbell-Thompson M, Aramandla R, Poffenberger G, Lindner J, Pan FC, von Herrath MG, Greiner DL, Shultz LD, Sanyoura M, Philipson LH, Atkinson M, Harlan DM, Levy SE, Prasad N, Stein R, Powers AC.

Cell Rep. 2018 Mar 6;22(10):2667-2676. doi: 10.1016/j.celrep.2018.02.032.

7.
8.

Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.

Rydén AK, Perdue NR, Pagni PP, Gibson CB, Ratliff SS, Kirk RK, Friesen TJ, Haase C, Coppieters K, von Herrath MG, Boursalian TE.

J Autoimmun. 2017 Nov;84:65-74. doi: 10.1016/j.jaut.2017.07.006. Epub 2017 Jul 12.

PMID:
28711285
9.

Alpha cells, the main source of IL-1β in human pancreas.

Anquetil F, Sabouri S, Thivolet C, Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, Schneider D, Castillo E, Lajevardi Y, von Herrath MG.

J Autoimmun. 2017 Jul;81:68-73. doi: 10.1016/j.jaut.2017.03.006. Epub 2017 Mar 18.

10.

Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset.

Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, Castillo E, Lajevardi Y, Krogvold L, Dahl-Jørgensen K, von Herrath MG.

Diabetes. 2017 May;66(5):1334-1345. doi: 10.2337/db16-1343. Epub 2017 Jan 30.

11.

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.

Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10.

PMID:
28094469
12.

Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?

Campbell-Thompson ML, Atkinson MA, Butler AE, Giepmans BN, von Herrath MG, Hyöty H, Kay TW, Morgan NG, Powers AC, Pugliese A, Richardson SJ, In't Veld PA.

Diabetologia. 2017 Apr;60(4):753-755. doi: 10.1007/s00125-016-4195-x. Epub 2017 Jan 9. No abstract available.

13.

A Deeper Look into Type 1 Diabetes - Imaging Immune Responses during Onset of Disease.

Christoffersson G, von Herrath MG.

Front Immunol. 2016 Aug 15;7:313. doi: 10.3389/fimmu.2016.00313. eCollection 2016. Review.

14.

The viral paradigm in type 1 diabetes: Who are the main suspects?

Rodriguez-Calvo T, Sabouri S, Anquetil F, von Herrath MG.

Autoimmun Rev. 2016 Oct;15(10):964-9. doi: 10.1016/j.autrev.2016.07.019. Epub 2016 Aug 1. Review.

PMID:
27491567
15.

Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Pham MN, von Herrath MG, Vela JL.

Front Immunol. 2016 Jan 11;6:651. doi: 10.3389/fimmu.2015.00651. eCollection 2015. Review.

16.

Erratum. Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes. Diabetes 2014;63:3880-3890.

Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG.

Diabetes. 2016 Jan;65(1):303. doi: 10.2337/db16-er01. No abstract available.

17.

Heterogeneity and Lobularity of Pancreatic Pathology in Type 1 Diabetes during the Prediabetic Phase.

Rodriguez-Calvo T, Suwandi JS, Amirian N, Zapardiel-Gonzalo J, Anquetil F, Sabouri S, von Herrath MG.

J Histochem Cytochem. 2015 Aug;63(8):626-36. doi: 10.1369/0022155415576543.

18.

Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for success.

Rekers NV, von Herrath MG, Wesley JD.

Clin Immunol. 2015 Nov;161(1):37-43. doi: 10.1016/j.clim.2015.05.021. Epub 2015 Jun 27. Review.

19.

Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.

von Herrath MG, Korsgren O, Atkinson MA.

Clin Exp Immunol. 2016 Jan;183(1):1-7. doi: 10.1111/cei.12656. Epub 2015 Jul 24. Review.

20.

Enterovirus infection and type 1 diabetes: closing in on a link?

Rodriguez-Calvo T, von Herrath MG.

Diabetes. 2015 May;64(5):1503-5. doi: 10.2337/db14-1931. No abstract available.

Supplemental Content

Loading ...
Support Center